% | $
Quotes you view appear here for quick access.

Infinity Pharmaceuticals, Inc. (INFI) Message Board

  • getintoh20 getintoh20 Jul 5, 2013 8:45 AM Flag

    Goldman Sachs today slashes pt from $40 to $20 Code word for SELL

    Goldman Sachs today maintained a Neutral rating on Infinity Pharmaceutical (NASDAQ: INFI) and cuts its price target to $20.00 (from $40.00). Analyst Navdeep Singh noted increased competitive pressures.

    "We are lowering our 12-month price target for INFI to $20 (from $40) due to (1) increased competitive pressure from Gilead's (Nasdaq: GILD) idelalisib, (2) uncertainty on IPI-145's (oral therapy for blood cancers) safety profile, and (3) lack of visibility on commercial positioning. We now project IPI-145 peak sales of $1bn (from $2.8bn) and assign no success (from a 20% probability of success) to retaspimycin (HSP-90 inhibitor for lung cancer) due to mixed competitor data at ASCO," said Singh.

    For an analyst ratings summary and ratings history on Infinity Pharmaceutical (NASDAQ: INFI) click here. For more ratings news on Infinity Pharmaceutical click here.

    Like i said going under $11. Short at well....Another great day for us shorts....

    SortNewest  |  Oldest  |  Most Replied Expand all replies
8.68+0.36(+4.33%)Nov 25 4:00 PMEST